Neurologic Imaging

What Imaging Is Best for Surveillance of Treated Paranasal Sinus Cancer?

·
What Imaging Is Best for Surveillance of Treated Paranasal Sinus Cancer?

It’s late in your clinic day, and you’re seeing a 68-year-old patient for a follow-up visit. Eighteen months ago, he completed a rigorous course of surgery and chemoradiation for squamous cell carcinoma of the ethmoid sinus. Today, he reports a new, persistent, dull ache behind his right eye and a sense of fullness. While it could be post-treatment change or benign sinusitis, the primary concern is tumor recurrence. You need to order the right imaging study to differentiate scar from cancer in a complex, previously treated anatomical field. This article details the clinical workflow for this specific scenario: surveillance or follow-up imaging for treated cancer of the paranasal sinuses or nasal cavity. According to the American College of Radiology (ACR) Appropriateness Criteria, an MRI of the orbits, face, and neck without and with IV contrast is Usually appropriate as the first-line imaging study.

Who Fits This Clinical Scenario?

This guidance is specifically for patients with a confirmed history of cancer originating in the paranasal sinuses (maxillary, ethmoid, sphenoid, frontal) or the nasal cavity, who have completed definitive treatment (e.g., surgery, radiation therapy, chemotherapy, or a combination). The imaging is being ordered for one of two reasons:

  • Routine Surveillance: Asymptomatic follow-up at a scheduled interval to monitor for subclinical recurrence.
  • Symptomatic Follow-up: The patient presents with new or worsening symptoms concerning for recurrence, such as new facial pain, numbness, vision changes, nasal obstruction, or a new neck mass.

It is critical to distinguish this scenario from similar but distinct clinical presentations that require a different imaging approach. This guidance does not apply to:

  • Initial Staging of a New Diagnosis: A patient with a newly discovered mass in the paranasal sinuses who has not yet undergone treatment falls under a different ACR variant. The imaging goals for initial staging are different from those of post-treatment surveillance.
  • Treated Nasopharyngeal Cancer: Cancers of the nasopharynx have a different biological behavior, including a strong association with Epstein-Barr Virus (EBV) and distinct patterns of spread. They are covered in a separate ACR scenario.
  • Treated Oral Cavity or Laryngeal Cancer: These cancers have different primary locations and routes of spread, necessitating a different imaging focus.

Applying the correct workflow starts with confirming your patient fits this specific post-treatment sinonasal cancer context.

What Diagnoses Are You Working Up in This Scenario?

In the post-treatment setting, imaging aims to distinguish between expected changes and pathological recurrence. The differential diagnosis is narrow but has high stakes.

Local Tumor Recurrence: This is the most pressing concern. Recurrence can manifest as a new or enlarging soft-tissue mass within the original tumor bed, the surgical cavity, or along the margins of resection. Differentiating this from scar tissue is the central challenge.

Perineural Tumor Spread: Sinonasal malignancies, particularly adenoid cystic carcinoma, have a high propensity for spreading along nerves (perineural spread). This can be clinically silent until advanced. Imaging must meticulously evaluate the cranial nerves traversing this region, such as branches of the trigeminal (V2, V3) and facial nerves.

Regional Nodal Metastasis: The cancer may recur not at the primary site but in the cervical lymph nodes. The appearance of new, enlarged, or necrotic-appearing lymph nodes in the neck is highly suspicious for regional recurrence.

Post-Treatment Changes (Mimics of Recurrence): The primary confounder is the sequelae of therapy. Radiation can cause inflammation (mucositis), fibrosis (scarring), and bone changes (osteoradionecrosis), all of which can enhance with contrast and be difficult to distinguish from tumor. Similarly, surgical changes, including flaps and grafts, alter the normal anatomy and can obscure underlying pathology.

Why Is MRI of the Orbits, Face, and Neck the Recommended Study?

For surveillance of treated sinonasal cancer, the ACR panel designates MRI of the orbits, face, and neck without and with IV contrast as Usually appropriate. The rationale is grounded in MRI’s superior ability to solve the core diagnostic problem: differentiating recurrent tumor from post-treatment scar tissue in an anatomically complex region.

MRI provides unparalleled soft-tissue contrast resolution. Different MRI sequences can distinguish between fibrosis, fluid, inflammation, and neoplastic tissue in ways that other modalities cannot. For instance, recurrent tumors typically demonstrate enhancement after gadolinium administration, while mature scar tissue often enhances less avidly or not at all. Furthermore, specific sequences like T2-weighted imaging can help differentiate tumor from post-obstructive secretions within the sinuses.

A key advantage of MRI in this scenario is its sensitivity for detecting perineural spread. Thickening and enhancement along the course of a cranial nerve is a specific and ominous sign of recurrence that is often only visible on high-resolution, contrast-enhanced MRI.

Finally, MRI involves no ionizing radiation (0 mSv). This is a crucial consideration for patients who will likely undergo multiple surveillance scans over many years, minimizing their cumulative radiation exposure.

Why are other studies rated lower for this specific purpose?

  • CT Neck with IV Contrast: While also rated Usually appropriate, CT is generally considered a secondary choice. It is excellent for assessing cortical bone destruction but provides inferior soft-tissue detail compared to MRI, making the core task of separating tumor from scar more difficult. It is a valuable alternative if a patient has a contraindication to MRI.
  • FDG-PET/CT Skull Base to Mid-thigh: Also rated Usually appropriate, PET/CT is highly sensitive for metabolically active disease. However, its primary limitation in the early post-treatment period (first 3-6 months) is low specificity. Radiation-induced inflammation is intensely FDG-avid and can cause false-positive results. PET/CT is often reserved as a problem-solving tool for equivocal findings on MRI/CT or for assessing for distant metastatic disease.

What’s Next After MRI? Downstream Workflow

The results of the surveillance MRI will guide the subsequent clinical pathway. The workflow typically branches based on the findings.

If the MRI is positive for recurrence: A finding of a new enhancing mass, perineural spread, or suspicious adenopathy necessitates a tissue diagnosis. The next step is typically a consultation with the head and neck surgeon for an endoscopic evaluation and biopsy of the suspicious area. The imaging is critical for guiding the surgeon to the precise location for the biopsy. If recurrence is confirmed, the patient will be re-evaluated by the multidisciplinary tumor board to determine options for salvage therapy, which may include further surgery, re-irradiation, or systemic therapy.

If the MRI is negative: A definitively negative scan provides reassurance. The patient can continue with their scheduled clinical follow-up and surveillance imaging protocol. No immediate further action is typically required.

If the MRI is indeterminate or equivocal: This is a common and challenging situation where post-treatment changes cannot be confidently distinguished from early recurrence. Several options exist. One is a short-interval follow-up MRI (e.g., in 6-8 weeks) to assess for change; a growing lesion is highly suspicious for tumor. Another option is to proceed with a complementary imaging study, such as an FDG-PET/CT, which provides functional information that may clarify the nature of the equivocal finding. Finally, if clinical suspicion remains high despite equivocal imaging, the surgeon may proceed with an examination under anesthesia and biopsy.

Pitfalls to Avoid (and When to Get Help)

Navigating post-treatment imaging requires careful attention to detail to avoid common errors.

  • Comparing to the Wrong Prior Study: Always ensure the radiologist has access to the immediate post-treatment baseline scan. The goal is to detect change over time, and this baseline is the most important reference point.
  • Misinterpreting Inflammatory Changes: In the first few months after radiation, intense mucosal enhancement and inflammation are normal. Attributing this to recurrence is a common pitfall. A close correlation with the time since treatment is essential.
  • Inadequate MRI Protocol: Ordering a generic “MRI Brain” is insufficient. The order must specify “Orbits/Face/Neck” with and without contrast and should include thin-section, high-resolution sequences through the skull base and fat-suppressed post-contrast images to properly evaluate for perineural spread.
  • Ignoring the Neck: The imaging field must extend inferiorly to include the entire cervical lymph node basin, as regional nodal recurrence can occur in isolation.

If findings are equivocal or the clinical picture does not match the imaging report, escalation to a multidisciplinary head and neck tumor board—including the radiologist, surgeon, radiation oncologist, and medical oncologist—is the standard of care.

Related ACR Topics and Tools

This article covers one specific scenario in depth. For a broader view of imaging across all head and neck cancer presentations, or to explore the tools used to make these decisions, the following resources are essential.

Frequently Asked Questions

How soon after treatment should the first surveillance scan be performed?

The timing of the first post-treatment scan is crucial. Most guidelines recommend obtaining a baseline scan, typically with MRI or CT, approximately 3 months after the completion of radiation therapy. This allows acute inflammatory changes to subside, providing a more stable baseline against which all future scans can be compared.

What if my patient has a pacemaker or other contraindication to MRI?

If a patient cannot undergo an MRI, a CT of the neck with IV contrast is the best alternative and is also rated ‘Usually appropriate’ by the ACR. While its soft-tissue resolution is lower than MRI’s, it is still a powerful tool, especially for evaluating bone and detecting nodal disease. An FDG-PET/CT is another strong option in this setting.

Is FDG-PET/CT better than MRI for surveillance?

Not necessarily for routine surveillance. While FDG-PET/CT is very sensitive, it can be prone to false positives due to post-radiation inflammation, especially in the first 6-12 months after treatment. It is often used as a second-line or problem-solving tool when MRI or CT findings are equivocal, or if there is a concern for distant metastatic disease.

Should I order an MRI without contrast to save time or cost?

No. For evaluating tumor recurrence, intravenous contrast is essential. Recurrent tumors are typically vascular and will enhance, which is often the key feature that distinguishes them from non-enhancing scar tissue or post-obstructive fluid. An unenhanced study is incomplete and inadequate for this clinical question.

How often should surveillance imaging be performed for an asymptomatic patient?

Surveillance schedules vary by institution and tumor characteristics (histology, stage), but a common approach involves more frequent imaging in the first 2-3 years post-treatment, when the risk of recurrence is highest. A typical schedule might be every 6 months for the first 2 years, then annually for another 3-5 years, in conjunction with regular clinical and endoscopic exams.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026